top of page
The Sound of Evolution
Montelukast
Mechanism of action:
Montelukast is a selective CysLT₁ receptor antagonist. Montelukast competitively inhibits the binding of leukotrienes LTC₄, LTD₄, and LTE₄ to CysLT₁ receptors on airway smooth muscle and immune cells, thereby reducing leukotriene-induced bronchoconstriction, airway edema, and mucus secretion.
Reference(s):
1. Falk NP et al. (2016). Medications for Chronic Asthma. Am Fam Physician.
2. Lu CY et al. (2015). Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors. Clin Ther.
bottom of page